Lu Tzu-Pin, Chen James J
Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, HFT-20, Jefferson, AR, 72079, USA.
Department of Public Health, Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan.
BMC Med Res Methodol. 2015 Dec 9;15:105. doi: 10.1186/s12874-015-0098-7.
Advances in molecular technology have shifted new drug development toward targeted therapy for treatments expected to benefit subpopulations of patients. Adaptive signature design (ASD) has been proposed to identify the most suitable target patient subgroup to enhance efficacy of treatment effect. There are two essential aspects in the development of biomarker adaptive designs: 1) an accurate classifier to identify the most appropriate treatment for patients, and 2) statistical tests to detect treatment effect in the relevant population and subpopulations. We propose utilization of classification methods to identity patient subgroups and present a statistical testing strategy to detect treatment effects.
The diagonal linear discriminant analysis (DLDA) is used to identify targeted and non-targeted subgroups. For binary endpoints, DLDA is directly applied to classify patient into two subgroups; for continuous endpoints, a two-step procedure involving model fitting and determination of a cutoff-point is used for subgroup classification. The proposed strategy includes tests for treatment effect in all patients and in a marker-positive subgroup, with a possible follow-up estimation of treatment effect in the marker-negative subgroup. The proposed method is compared to the ASD classification method using simulated datasets and two publically available cancer datasets.
The DLDA-based classifier performs well in terms of sensitivity, specificity, positive and negative predictive values, and accuracy in the simulation data and the two cancer datasets, with superior accuracy compared to the ASD method. The subgroup testing strategy is shown to be useful in detecting treatment effect in terms of power and control of study-wise error.
Accuracy of a classifier is essential for adaptive designs. A poor classifier not only assigns patients to inappropriate treatments, but also reduces the power of the test, resulting in incorrect conclusions. The proposed procedure provides an effective approach for subgroup identification and subgroup analysis.
分子技术的进步已使新药开发转向针对有望使部分患者亚群受益的靶向治疗。适应性特征设计(ASD)已被提出用于识别最合适的目标患者亚组,以提高治疗效果。生物标志物适应性设计的发展有两个关键方面:1)一种准确的分类器,用于为患者确定最合适的治疗方法;2)用于检测相关总体和亚组中治疗效果的统计检验。我们建议利用分类方法来识别患者亚组,并提出一种统计检验策略来检测治疗效果。
对角线性判别分析(DLDA)用于识别靶向和非靶向亚组。对于二元终点,DLDA直接用于将患者分为两个亚组;对于连续终点,采用包括模型拟合和确定临界点的两步程序进行亚组分类。所提出的策略包括对所有患者和标志物阳性亚组的治疗效果进行检验,并可能对标志物阴性亚组的治疗效果进行后续估计。使用模拟数据集和两个公开可用的癌症数据集,将所提出的方法与ASD分类方法进行比较。
基于DLDA的分类器在模拟数据和两个癌症数据集中,在敏感性、特异性、阳性和阴性预测值以及准确性方面表现良好,与ASD方法相比具有更高的准确性。亚组检验策略在检测治疗效果的效能和控制研究总体误差方面被证明是有用的。
分类器的准确性对于适应性设计至关重要。一个较差的分类器不仅会将患者分配到不适当的治疗中,还会降低检验效能,导致错误的结论。所提出的程序为亚组识别和亚组分析提供了一种有效的方法。